Response among evaluable patients and selected subgroups
| . | Patients (n = 25), n (%) . |
|---|---|
| Response | |
| VGPR | 6 (24) |
| PR | 7 (28) |
| MR | 6 (24) |
| Stable disease | 4 (16) |
| Progressive disease | 2 (8) |
| VGPR and PR in selected subgroups | 13 |
| Previous use of thalidomide only | 4 (31) |
| Previous use of lenalidomide only | 5 (38) |
| Previous use of thalidomide + lenalidomide | 3 (23) |
| No previous use of thalidomide or lenalidomide | 1 (8) |
| . | Patients (n = 25), n (%) . |
|---|---|
| Response | |
| VGPR | 6 (24) |
| PR | 7 (28) |
| MR | 6 (24) |
| Stable disease | 4 (16) |
| Progressive disease | 2 (8) |
| VGPR and PR in selected subgroups | 13 |
| Previous use of thalidomide only | 4 (31) |
| Previous use of lenalidomide only | 5 (38) |
| Previous use of thalidomide + lenalidomide | 3 (23) |
| No previous use of thalidomide or lenalidomide | 1 (8) |
VGPR indicates very good partial remission; PR, partial remission; and MR, minor remission.